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Objectives: The purpose of this study is to describe trends in the utilization of antihypertensive medications, overall
and by type of medication, specifically thiazide diuretics, as well as uncontrolled hypertension, in the Palestine refugee
population in Jordan between 2008 and 2012.
Methods: We analyzed aggregate procurement data on antihypertensive medications derived from the United Nations
Relief and Works Agency (UNRWA) pharmacy records between 2008 and 2012. Antihypertensive medications were
aggregated and utilization was calculated overall and for specific types of antihypertensive medications (e.g. β-blockers,
diuretics). We used the WHO (World Health Organization) defined daily dose (DDD) methodology, often used to evaluate
drug utilization patterns using aggregate data, to calculate utilization defined as DDDs per 100 persons with hypertension.
In addition, UNRWA medical records were used to measure the prevalence of uncontrolled hypertension in the primary
care setting. Uncontrolled hypertension was defined as a systolic/diastolic blood pressure ≥140/90 in at least 2 out of 3
readings, one of which is the most recent reading, during the year for a patient diagnosed with hypertension.
Results: Overall, total utilization of antihypertensive medications has not changed between 2008 and 2012;
hypertensive patients persistently used at least 2 antihypertensive medications daily (range 200–280 DDDs/100
patients with hypertension) during this five-year period. However, there is significant variation in utilization patterns by
type of antihypertensive medication. While Angiotensin Converting Enzyme Inhibitors (ACE-I) were persistently the
most commonly used antihypertensive medication, there utilization significantly (P < 0.05) declined by 26%. However,
there was a statistically significant increase of 124% in the utilization of thiazide diuretics. Further, the prevalence of
uncontrolled hypertension has also declined at a rate of 3% annually between 2008 and 2012.
Conclusion: Our findings indicate that the STGs for hypertension management implemented in 2009 as part of
UNRWA's essential drug program have increased the utilization of thiazide diuretics, and potentially contributed
to improvements in hypertension control. This study also demonstrates that feasibility of drug utilization studies
in monitoring and evaluating trends in the use of essential medications in low-resource settings.
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Hypertension is a persistent and leading risk factor for
cardiovascular morbidity and mortality globally [1], in-
cluding countries in the Middle East for which there is a
substantial, yet often overlooked, population of Palestine
refugees [2]. As of 2012, there were more than 5 million
Palestine refugees living in Jordan, Lebanon, Syria and
Palestine (West Bank and Gaza) with more than 15% of
the adult population suffering from hypertension, 30% of
which are considered high risk [3]. Since 1951, the United
Nations Relief and Works Agency (UNRWA) has been
responsible for the delivery of primary health care (PHC)
services at no cost, including the provision of essential
medicines such as antihypertensive medications, for this
chronically vulnerable refugee population [3,4]. Despite
the critical role of antihypertensive medications in the
management of hypertension, and in the prevention of
complications associated with uncontrolled hypertension,
there is currently no information on their utilization in the
Palestine refugee population.
Understanding the utilization of antihypertensive medi-
cations among Palestine refugees is particularly important
for several reasons. First, hypertension is increasingly
prevalent in an aging refugee population, [3] and infor-
mation on whether patterns in the utilization of antihy-
pertensive medications align with treatment guidelines is
imperative for ongoing efforts to improve hypertension
management. This is particularly important considering
UNRWA’s 2009 implementation of evidence-based stand-
ard treatment guidelines (STGs) which relied on the
hypertension treatment recommendations of the Joint Na-
tional Commission-VII (JNC-7) [5] that have since been
updated to JNC-VIII [6]. The impact of these STGs on the
utilization of antihypertensive medications, however, is
not known. Second, over the last several years UNRWA
spending on antihypertensive medications has increased
with annual expenditures totaling more than $1.8 million
in 2012 [7]. Thus, understanding whether trends and pat-
terns of antihypertensive medication utilization not only
align with STGs, but are also effective in improving hyper-
tension control is critical in reducing complications and
costs associated with uncontrolled hypertension. Finally,
ensuring the essential medicines program, anchored in hu-
man rights principles, [8,9] effectively promotes better
health in an under-recognized and often ignored popula-
tion of Palestine refugees is a humanitarian imperative.
In order to better characterize patterns of antihyper-
tensive medication use in the Palestine refugee popula-
tion, we leverage existing data derived from UNRWA
pharmacy procurement records for Jordan to describe
trends in the utilization of antihypertensive medications
between 2008 and 2012, and discuss the potential impact
of STG implementation on utilization patterns as hyper-
tension control We focus on Jordan because it has morethan 2 million UNRWA Palestine refugees, which, aside
from Palestine, is the largest population of Palestine
refugees in the Middle East [4].
Methods
We used existing aggregate procurement data derived
from the UNRWA pharmacy records to examine the
utilization of antihypertensive medications between 2008
and 2012 in Jordan. UNRWA procurement data captures
detailed information on quantities, strength and dosage
forms of medications distributed to patients that utilize
UNRWA PHCs in Jordan. These data are not directly
linked to patient records.
We also retrieved de-identified information on blood
pressure readings from the UNRWA PHC health man-
agement information system (HMIS) for patients with a
diagnosis of hypertension, We used this information to
describe the annual prevalence of uncontrolled hyperten-
sion among the Palestine refugee patient population treated
by general practitioners at the UNRWA PHCs in Jordan
between 2008 and 2012 . Uncontrolled hypertension was
defined as a systolic/diastolic blood pressure ≥140/90 in 2
out of 3 readings, one of which is the most recent reading,
during the treatment year.
Antihypertensive medications were classified based
on the World Health Organization (WHO) Anatomic
Therapeutic Chemical (ATC) system which are depicted
in Table 1 [10].
We also used the WHO defined daily dose (DDD) meth-
odology, which is often used to evaluate drug utilization
using aggregate data, to calculate utilization of antihyper-
tensive medications using our procurement data. We ob-
tained the DDD values from the WHO ATC/DDD index
to derive DDDs for each medication. DDD is a measure
that represents that average daily maintenance dose for
the main indication of a drug in adults. It is used to aggre-
gate data on different doses, strengths, and formulations
to enable comparisons of utilization across different medi-
cations, different populations and over time. For example,
10 DDDs/100 patients per day for a medication or class of
medications indicates that 10% of the population on aver-
age receive a certain medication or group of medications
daily. In our study, utilization is defined as number of
DDDs per 100 persons with hypertension (patient popula-
tion) per day. Our hypertension sample was based on the
number of patients over the age of 40 diagnosed with
hypertension at UNRWA PHCs between 2008 and 2012
(Table 2).
The number of DDDs for all antihypertensive medica-
tions were aggregated and utilization was calculated for
antihypertensive medications overall, by antihypertensive
therapeutic category (e.g. β-blockers, diuretics) and for
individual antihypertensive medications (e.g. enalapril).
With the exception of amiloride/hydrocholorothiazide
Table 1 Changes in the utilization (DDDs per 100 hypertensive patients per year) of antihypertensive medications
among the Palestine refugee hypertensive patient population in Jordan between 2008 (pre-STG) and 2012 (post-STG)
ATC codes Therapeutic class Antihypertensive utilization,
% of total
Change in utilization Percent change in utilization
2008 2012 2008-2012 2008-2012
Total** 280.5 (100%) 275.3(100%) −5.23 −1.86%
C02AB01 Alpha-adrenergic
agonists
2.22 (0.8%) 2.55 (0.9%) +0.33 +14.86%
C09AA02 ACE inhibitors** 178.1 (63.5%) 132.5 (48.1%) −45.67 −25.64%
C09CA01 Angiotensin II receptor
antagonists**
0 (0%) 7.7 (2.8%) +7.71 -
C07AA05, C07AB03 Beta blockers 53.9 (19.2%) 55.4 (20.1%) +1.43 +2.65%
C08CA05, C08DB01, C08CA01 Calcium channel
blockers
23.8 (8.5%) 26.97 (9.8%) +3.2 +13.46%
C03AA03,C03AX01,
C03CA01,C03DB01
Diuretics** 22.4 (8.0%) 50.2 (18.2%) +27.77 +123.9% (only more than 100%
is significant)
DDD = defined daily dose, ACE = Angiotensin-converting enzyme; Standard Treatment Guidelines (STG) for hypertension management implemented in 2009 at
UNRWA primary health clinics (PHCs).
**The binomial proportion 95% confidence interval excludes the null value of zero difference (P-value <0.05).
Saadeh et al. Journal of Pharmaceutical Policy and Practice  (2015) 8:17 Page 3 of 8combination product procured in 2012, all medication
products were single-ingredient products. We describe
the prevalence of antihypertensive utilization measured
as DDD/100 persons with hypertension between 2008
and 2012.
We used simple linear regression models to calculate
the trend (change in DDD per 100 hypertensive pa-
tients). We also used the t-test to determine the statis-
tical significance of the trend (change in DDD over
time) between all therapeutic categories (Figure 1) and
between individual types of medications (Figure 2). A
statistically significant change in the utilization of anti-
hypertensive medications overall and by therapeutic
class between 2008 and 2012 was also examined based
on the exclusion of zero difference in the 95% binomial
confidence interval. F-test was conducted to assess dif-
ferences in trends between the drug classes. All analyses
were conducted in SAS statistical software. Patient in-
formation was de-identified prior to analyses. This
study was approved by the University of Illinois Institu-
tional Review Board that is responsible for the ethics of




(% of total registered population)
Served populat
years
2008 1,951,603 1104607 (56.6%) 307,935
2009 1,983,733 1110890 (56.0%) 312,953
2010 1,999,485 1050035 (52.5%) 324,743
2011 2,047,367 1074251(52.5%) 323,423
2012 2,110,114 1175021(55.7%) 367,434
*Number of Palestine refugees that utilize UNRWA Primary Health Care (PHC) servicinformed consent was obtained from the patient for the
publication of this report and any accompanying images
Results
Table 2 provides a summary of the refugee population
served by UNRWA PHCs and the prevalence of hyperten-
sion between 2008 and 2012. In 2012, more than 1 million
people utilized the UNRWA PHCs with approximately
400,000 aged ≥40 years. According to these data derived
from UNRWA medical records, the number of refugees
with hypertension in Jordan has increased between 2008
and 2012. However, the prevalence of hypertension has
not changed substantially between 2008 and 2012. In
2012, 53,278 patients or 14.5% of the served population
aged ≥ 40 years was diagnosed with hypertension (de-
fined as systolic/diastolic blood pressure ≥ 140/90).
Figure 1 depicts trends in the utilization (DDDs per
100 hypertension patients per day or DDDs) for antihy-
pertensive medications overall and by therapeutic class
for the UNRWA refugee hypertensive patient popula-
tion. Overall, hypertensive patients used at least 2 anti-
hypertensive medications daily (or 2 DDDs per patientgee Population ≥ 40 years in Jordan, 2008–2012
ion≥ 40 Number of patients ≥ 40 years
with a Diagnosis of Hypertension
Prevalence of hypertension







Figure 1 Trends in the defined daily dose (DDD) of antihypertensives overall and by type of drug classes per 100 patients from 2008 to 2012.
The trend (change in DDD per 100 patients) was calculated using simple linear regression model. T-tests for change in DDD per 100 patients
across years was not statistically significant for antihypertensives overall [P = 0.787].T-tests for change in DDD per 100 patients across years was
statistically significant for diuretics [P = 0.044]. F-test for differences in trends between the drug classes was statistically significant [P = 0.009].
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age decline (−2.86 DDDs/year) for all hypertensive medi-
cations was not statistically significant (p-value = 0.787).
However, there was a statistically significant difference in
utilization over time between antihypertensive therapeutic
classes. For example, the only significant trend or annual
change over time was for the utilization of diuretics (+6.03
DDDs; p < 0.05). While there was a notable decline in the
utilization of ACE-I (−11.3/year), the trend was not statis-
tically significant.
Table 1 summarizes changes in utilization of antihyper-
tensive medication by ATC code and therapeutic category
between 2008 (base year) and 2012. The utilization of anti-
hypertensive medications slightly declined from 280.5 to
275.3 DDDs between 2008 and 2012 (+5.23 DDDs [95%
CI 0.87-9.59]). The utilization of ACE-I declined by 25%
from 178.14 to 132.47 DDDs (−45.7 DDDs [95% CI 35.91-
55.43]). However, ACE-I persistently accounted for the
majority of antihypertensive medication utilization; 64%
and 48% of total DDDs from antihypertensive medica-
tions in 2008 and 2012, respectively, were for ACE-I.
Further, angiotensin II receptor antagonist were not
utilized between 2008 and 2011, but accounted for 7.7
DDDs in 2012.
The most substantial increase in utilization was observed
for diuretics (123.9%). Diuretics significantly (P-value <
0.05) increased from 22.4 DDDs to 50.2 DDDs per 100hypertensive patients (+27.8 DDD [95% CI 18.99-36.55]) in
2008 and 2012, respectively. Our results do not indicate a
statistically significant change in trends in the utilization of
other classes of antihypertensive medications.
Figure 2 depicts trends in the utilization of specific an-
tihypertensive medications by therapeutic class. Among
β-blockers, the utilization of propranolol was consist-
ently lower than atenolol during the 5-year time period.
Although the use of atenolol increased from 53.1 to
55.41 DDDs per 100 hypertensive patients (+0.45 DDDs/
year) during this observation period, the increase was
not significant. The decline (−0.90 DDDs per 100 hyper-
tensive patients) in the utilization of propranolol was
also not significant during this period (P = 0.34).
Among ACE-I and angiotensin II receptor antagonists,
enalapril’s utilization declined from 178.14 to 132.47
DDDs per 100 hypertensive patients (−11.33 DDDs/year)
between 2008 and 2012. This decline (−45.7 DDDs per
100 hypertensive patients) was the largest among all an-
tihypertensive medications. Losartan potassium was only
used among the UNRWA patients in Jordan during the
year 2012 (7.71 DDDs per 100 hypertensive patients).
Among calcium channel blockers, the utilization of ni-
fedipine and diltiazem hydrochloride declined by 22.6 and
0.81 DDDs per 100 hypertensive patients, respectively.
The change in the utilization of diltiazem hydrochloride
was not significant (P = 0.519). Nifedipine’s utilization was
Figure 2 Trends in the defined daily dose (DDD) of antihypertensive drugs per 100 patients from 2008 to 2012. a-e The trend (change in DDD
per 100 patients) was calculated using simple linear regression model. T-tests for change in DDD per 100 patients across years was statistically
significant for propranolol [P = 0.033], diltiazem hydrochloride [P = 0.009] and hydrochlorothiazide [P = 0.001].
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2011. In 2012, no utilization was observed for nifedipine,
while amlopidine was utilized for the first time. Methyl-
dopa had the smallest increase in utilization (+0.33 DDDs
per 100 hypertensive patients) among all antihypertensive
drugs between 2008 and 2012.
All three diuretic medications had an increase in
utilization between 2008 and 2012. Amiloride, available
since 2010 to the UNRWA PHC patients, had thehighest increase in utilization (+12.86 DDDs per 100
hypertensive patients) among the diuretics during this
period. However, hydrochlorothiazide was consistently
the most commonly used diuretic and increased from
15.1 to 25.3 DDDs per 100 hypertensive patients during
this period (P = 0.062). The increase in the utilization
(+4.27 DDDs per 100 hypertensive patients) of fur-
osemide was the lowest among diuretics during the
5-year time period.
Saadeh et al. Journal of Pharmaceutical Policy and Practice  (2015) 8:17 Page 6 of 8Figure 3 illustrates the patterns in the prevalence of
hypertension as well as uncontrolled hypertension in the
UNRWA patient population for which these antihyper-
tensive medications were procured. Despite an increas-
ing prevalence of hypertension among patients aged 40
years and older, the number of patients with uncon-
trolled hypertension has significantly declined from
43.3% or 18,400 patients to 31.5% or 16,783 patients.
The decline in the prevalence of uncontrolled hyperten-
sion by 11.80% was statistically significant (P < 0.001).
The chi-square test for the difference in prevalence of
uncontrolled hypertension between 2008 and 2012 was
found to be statistically significant [P < 0.0001].
Discussion
To our knowledge, this is the first study to examine
trends in the utilization of medications in the Palestine
refugee patient population. We used readily available
procurement data derived from UNRWA pharmacy re-
cords to examine trends in the utilization of antihyper-
tensive medications among Palestine refugees in Jordan
between 2008 and 2012. Our findings indicate that the
total utilization of antihypertensive medications has not
changed substantially over time. However, trends in the
types of antihypertensive medications used and the
prevalence of uncontrolled hypertension has signifi-
cantly improved among the Palestine refugee patient
population. This initial drug utilization study increases
our understanding of the effectiveness of UNRWA’s
essential medicines program, particularly the STG’s, in
improving cardiovascular health, particularly hyperten-
sion, in Palestine refugees.Figure 3 Prevalence of uncontrolled hypertension among the Palestine re
in prevalence of hypertension) was calculated using simple linear regressio
hypertension across years were not statistically significant [P = 0.396 and P
hypertension per year was 0.29%. The average decrease in the percentage
year was 2.87%.Palestine refugees with hypertension were persistently
using, on average, between two and three antihyperten-
sive medications daily, suggesting combination therapy
regimens were common. Angiotensin Converting En-
zyme Inhibitors (ACE-I) were the most commonly used
antihypertensive medication and accounted for the ma-
jority of antihypertensive medications throughout the 5-
year period. However, ACE-I utilization declined in 2012
and was being replaced by diuretics, which may have im-
portant clinical implications in the prevention of complica-
tions in hypertension patients with co-morbid conditions
such as diabetes, such as renal impairment, and warrants
further investigation.
Between 2008 and 2012, the use of diuretics increased
more than two-fold, particularly hydrochlorothiazide.
The utilization of all other types of antihypertensive
medications did not change. These findings are not sur-
prising considering the JNC-VII hypertension treatment
guidelines that recommend diuretics, specifically thiazide
diuretics, as first-line agents and suggest the STGs up-
dated in 2009 were an effective strategy in improving
prescribing, and consequently, utilization of antihyper-
tensive medications among the UNRWA patient popula-
tion. However, the thiazide diuretics are not always
indicated in the management of hypertension, for ex-
ample in diabetic patients, and further investigation of
these utilization patterns in the patient population would
better elucidate the appropriateness of the patterns we
observed in this study.
While the utilization of β-blockers did not change be-
tween 2008 and 2012, it was persistently greater than the
utilization of diuretics. However, the difference lessenedfugee population (>40 years old) from 2008 to 2012. The trend (change
n model. T-tests for change in prevalence of any and uncontrolled
= 0.130, respectively]. The average increase in the prevalence of any
of hypertensive patients with uncontrolled high blood pressure per
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These changing patterns of antihypertensive utilization
are important considering the updated JNC-VIII [6]
hypertension treatment guidelines that recommend β-
blockers only as later line alternative therapies. Therefore
the current UNRWA STGs should be revised to better
align with the JNC-VIII guidelines (vs. JNC-VII) that dis-
courage the use of β-blockers that have been associated
with a differential risk for cardiovascular events [11].
Trends in the prevalence of uncontrolled hypertension
were also improving during the same 5-year period. The
gradual decline in the prevalence of uncontrolled hyper-
tension among the patient population to 31% is notable,
and may be associated with the increasing use of thia-
zide diuretics in combination with ACE-I which are the
recommended first-line therapies in the current JNC-
VIII guidelines [6]. Our findings suggest that program-
ming efforts to improve the appropriate use of essential
medicines in the Palestine refugee population have
potentially important implications on health outcomes
such as lower incidence of cardiovascular complications
(e.g. myocardial infarction, heart failure, and stroke)
often associated with uncontrolled hypertension [12].
Future investigations should include patient-level ana-
lyses that better examine the impact of appropriate use
of antihypertensive medications across various cardio-
vascular risk profiles, and their associated outcomes, in
Palestine refugee.
Improvement in both the utilization of antihyperten-
sive medications, and uncontrolled hypertension, is par-
ticularly noteworthy in comparison to findings for the
general population in Jordan. For example, a study con-
ducted in 2009 examined antihypertensive medication
use for 416 men and women patients aged 18–94,
undergoing hypertension management at primary health
care clinics in Jordan. This study found combination
therapy with β-blockers and diuretics to be the most fre-
quently used antihypertensive therapeutic regimen [13].
While JNC-VII guidelines had recommended diuretics
or β-blockers as first line therapies, their combined use
is suboptimal as evident in the high prevalence (more than
50%) of uncontrolled hypertension (SBP/DBP ≥140/90) in
the patient population. These findings further suggest that
implementation of STGs are often critical in promoting
the appropriate use of medicines in the management of
NCD such as hypertension [14].
Finally, our study demonstrates the feasibility of con-
ducting drug utilization studies in refugee settings using
procurement data derived from existing pharmacy re-
cords. Our findings further suggest that drug utilization
studies can be used as a tool to monitor and evaluate the
effectiveness of essential medicines programs, such as
adherence to standard treatment guidelines in primary
health care. Future studies should examine the utilizationof medications for other common and costly non com-
municable diseases (NCDs) such as diabetes, hyperchol-
esterolemia, and chronic obstructive pulmonary disease
(COPD).
Limitations
Our study has several limitations. The use of aggregate
procurement data may not adequately represent utilization
or appropriateness of treatment at the individual level. For
example, we are unable to discern differences in the types
of medications use as mono- or combination therapy at
the patient-level. Therefore we are unable to specifically
identify what combinations were used, and whether and
how they affect hypertension control at the patient level.
Our data on both the utilization of antihypertensive medi-
cations and the prevalence of uncontrolled hypertension
represents patients undergoing treatment at UNRWA
PHC and may not be generalizable to the general Palestine
refugee population. Therefore, future studies should inves-
tigate the use of medicines, and specific health outcomes
measures, in the community setting.
Conclusions
While trends in the total utilization of antihypertensive
medications have not changed between 2008 and 2012,
the types of antihypertensive medications used and the
prevalence of uncontrolled hypertension has significantly
improved among Palestine refugees in Jordan. Our find-
ings indicate that the STGs for hypertension management
implemented in 2009 as part of UNRWA’s essential drug
program have not only increased the utilization of thiazide
diuretics, which better aligns with international treatment
guidelines for hypertension, but have potentially contrib-
uted to improvements in hypertension control. Future
research to examine the patterns in the utilization antihy-
pertensive medications, and hypertension control, at the
community-level are warranted.
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